New Street Investor Relations的动态

TrueBinding has cleared an FDA IND application for TB006 for potential disease modification of Parkinson’s Disease. A multi-center, placebo-controlled, Phase 2A trial of TB006 in the U.S. will be evaluating the safety and efficacy of this treatment in patients with Hoehn and Yahr grade 1 or 2 Parkinson’s Disease. https://lnkd.in/gfT_yHac

As someone deeply passionate about healthcare innovation, I believe the significance of Beckman Coulter receiving US FDA Breakthrough Device Designation for our Access p?Tau217/β-Amyloid 1-42 plasma ratio test is the promise it holds for the future of patient care.?By prioritizing reviews, as well as enhanced communication and regulatory support, this Breakthrough Device Designation is not just an FDA regulatory milestone – it represents our commitment to advancing patient care through innovative technology and expedited development processes.

Great to see better patient outcomes in TED (thyroid eye disease) on the horizon with better than expected clinical results...even after just one infusion. https://lnkd.in/e6udmAft

AMBAR: A Therapeutical Approach for Alzheimer’s Disease Patients Regardless of Amyloid Status. Costa, M., @MerceBoadaR. https://lnkd.in/efx_UANp #AlzheimersDisease #Amyloid

Topline results from AbbVie’s phase 3 TEMPO-2 trial of tavapadon as a flexible-dose monotherapy revealed that the treatment met its primary and secondary end points in patients with early #Parkinsons disease. #MovementDisorder https://lnkd.in/esPMXfce

John Mascarenhas, MD, discusses his research on the four hallmarks of myelofibrosis and how they were observed in patients receiving combination therapy versus standard treatment in JAK inhibitor-naive disease. https://lnkd.in/eM7spMPU

https://lnkd.in/e4vEfRBH an obvious, yet difficult next question to develop and answer. Not only is there residual disease/partial response to systemic therapy, but why... and do we have a more targetted next intervention to use. This is a good foundation upon which to build the next layer of precision based question, answers, strategies, and conversations.

Outstanding findings from Cerevance's Phase 2 clinical trial! ?? Their novel development, solengepras, shows promising results in reducing OFF time for Parkinson’s patients. Read the full study published in eClinicalMedicine here. ?????

Many thanks to Betsy Goodfellow at Pharmafile.com for featuring an article by Dr Dan Williams. Dan considers the ongoing challenges facing rare disease patients, and discusses developments in the search for therapies. The full story is here: https://lnkd.in/e_58twVs

As we begin 2025, here is a review of all the Huntington’s disease research news and the progress the field has made in the last 12 months from HDBuzz: